Medtronic (NYSE:MDT) Issues FY 2027 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY 2027 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 5.940-6.000 for the period, compared to the consensus earnings per share estimate of 5.950. The company issued revenue guidance of -. Medtronic also updated its Q2 2027 guidance to 1.320-1.340 EPS.

Medtronic Stock Performance

Shares of Medtronic stock opened at $91.92 on Wednesday. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The company has a 50 day moving average price of $86.03 and a 200 day moving average price of $85.42. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33. The firm has a market capitalization of $117.66 billion, a P/E ratio of 24.64, a PEG ratio of 2.43 and a beta of 0.56.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.Medtronic’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Sell-side analysts expect that Medtronic will post 5.94 EPS for the current year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is 77.21%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on MDT shares. Needham & Company LLC upped their price target on shares of Medtronic from $101.00 to $114.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a research note on Thursday, June 4th. JPMorgan Chase & Co. reduced their price target on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Wells Fargo & Company reiterated an “overweight” rating on shares of Medtronic in a report on Wednesday. Finally, Leerink Partners cut their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. Nineteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $100.17.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.27% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q1 results exceeded expectations. Medtronic reported adjusted EPS of $1.45 versus the $1.39 consensus estimate, while revenue rose 13.7% year over year to $9.76 billion, topping estimates of approximately $9.55 billion. Growth was broad-based, led by cardiovascular revenue of $3.93 billion, up nearly 19% organically. Medtronic fiscal first-quarter results
• Positive Sentiment: Full-year guidance was raised. Medtronic increased fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00, with management citing strong demand for cardiovascular devices, newer growth platforms and improved margins. Medtronic raises fiscal 2027 forecast
• Positive Sentiment: Robotics expansion strengthens Medtronic’s growth strategy. The company plans to invest approximately $700 million in Hong Kong-based Cornerstone Robotics and obtain rights to distribute its Sentire surgical system in select approved markets outside the U.S. The system will complement Medtronic’s Hugo robotic platform, broadening its minimally invasive surgery offering. Medtronic Cornerstone Robotics partnership
• Positive Sentiment: Additional structural-heart investment supports future products. Medtronic will invest up to $80 million in Pi-Cardia, securing an option to strengthen its technology portfolio for complex transcatheter aortic valve replacement procedures. Analysts at William Blair reiterated a Buy rating, while BTIG raised its price target from $91 to $100.
• Neutral Sentiment: Second-quarter fiscal 2027 EPS guidance of $1.32-$1.34 was slightly below the $1.35 consensus, although full-year guidance remained broadly in line with expectations after the increase.
• Neutral Sentiment: The quarter benefited from an additional fiscal week, which contributed approximately $570 million to organic revenue, creating a comparison factor investors may monitor in coming periods.

Hedge Funds Weigh In On Medtronic

A number of institutional investors have recently bought and sold shares of MDT. Brighton Jones LLC raised its holdings in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares in the last quarter. Jump Financial LLC purchased a new position in shares of Medtronic during the 2nd quarter valued at about $299,000. Main Street Financial Solutions LLC grew its position in Medtronic by 28.9% during the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock worth $1,251,000 after acquiring an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its holdings in Medtronic by 21.3% in the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock worth $1,676,000 after buying an additional 3,376 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).